| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 205.9 | 213.7 |
| Gross profit | 157.2 | 164.9 |
| Profit before tax | -0.8 | 1.8 |
| Net income | -5.6 | -6.5 |
| EPS (diluted, $ a share) | $-0.30 | $-0.36 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -3.6% |
|---|---|
| Gross margin | 76.3% |
| Operating margin | -0.7% |
10-Q filed with the SEC, NYSE: USNA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Usana Health Sciences Inc: key numbers
- Share price
- $13.54Close, Nov 16
- Market cap
- $250M
- Shares outstanding
- 18.49MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Medicinal Chemicals & Botanical ProductsSIC 2833
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Usana Health Sciences Inc
All →Usana Health Sciences Financial Results
USANA Health Sciences reported third quarter 2026 net sales of $206 million and a net loss of $5.6 million. While Core Nutritional active customers declined year-over-year, the company saw an 18% sequential increase in Hiya active monthly subscribers and generated $36 million in year-to-date free cash flow.
- Term
- Q3 2026
“As we continue our transformation to an omnichannel health and wellness company, our third quarter results were mixed, with meaningful improvement in some areas and results that fell short of our expectations in others.”
Kevin Guest, Chairman and Chief Executive Officer
“In Core Nutritional, rebuilding our active customer base is our top priority and our single largest growth lever.”
Kevin Guest, Chairman and Chief Executive Officer
Usana Health Sciences $75M Debt Financing with Bank of America, N.A.
USANA Health Sciences entered into a first amendment to its $75 million revolving credit facility with Bank of America. The amendment modifies financial covenants, including a minimum consolidated EBITDA requirement of $100 million, and increases the annual limit for general asset disposals to $2.5 million. It also specifically permits the sale and potential leaseback of the company's real property in Sydney, Australia.
- Value
- $75M
- Counterparty
- Bank of America, N.A.
- Term
- through June 2030